AR071054A1 - Compuestos para usar en la formacion de imagenes el diagnostico y/o el tratamiento de enfermedades del sistema nervioso central o de tumores, metodos de preparacion, composiciones farmaceuticas, usos y metodos de deteccion de monoamina oxidasa. - Google Patents

Compuestos para usar en la formacion de imagenes el diagnostico y/o el tratamiento de enfermedades del sistema nervioso central o de tumores, metodos de preparacion, composiciones farmaceuticas, usos y metodos de deteccion de monoamina oxidasa.

Info

Publication number
AR071054A1
AR071054A1 ARP080104633A ARP080104633A AR071054A1 AR 071054 A1 AR071054 A1 AR 071054A1 AR P080104633 A ARP080104633 A AR P080104633A AR P080104633 A ARP080104633 A AR P080104633A AR 071054 A1 AR071054 A1 AR 071054A1
Authority
AR
Argentina
Prior art keywords
alkyl
compounds
compound
formula
diagnosis
Prior art date
Application number
ARP080104633A
Other languages
English (en)
Inventor
Lutz Lehmann
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of AR071054A1 publication Critical patent/AR071054A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Abstract

Compuestos que son apropiados para marcar o que ya están marcados con 18F, métodos para preparar estos compuestos, composiciones que comprenden estos compuestos, conjuntos de elementos que comprenden estos compuestos o composiciones, y usos de estos compuestos, composiciones o conjuntos de elementos para el diagnostico por imágenes por tomografía por emision de positrones (PET). Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1) o formula (2) en donde W se selecciona entre el grupo que comprende -C(U1)(U2)-C:::CH y ciclopropilo, U1 y U2 se seleccionan en forma independiente entre hidrogeno y deuterio; A se selecciona entre el grupo que comprende arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, tal como furanilo, alquilo C1-10, G4-alquinilo C2-4, G4-alcoxi C1-4, (G4-alquil C1-4)arilo, (G4-alcoxi C1-4)arilo, (G4-alquil C1-4)arilo, y (G4-alcoxi C1-4)arilo, en donde preferentemente dicho heteroarilo es furanilo, G1, G2, G3 y G4 en la formula (1) y formula (2) se seleccionan en forma independiente y en forma individual, en cada oportunidad, entre el grupo que comprende hidrogeno, alquilo C1-4, preferentemente metilo, L, y alquil C1-6-L, con la condicion de que exactamente uno de G1-G4 en la formula (1) se selecciona entre L y -alquil C1-6-L, y con la condicion de que exactamente uno de G3 y G4 en la formula (2) se selecciona entre L y -alquil C1-6-L, L es un grupo saliente, o L es F, preferentemente 18F o 19F, en donde, preferentemente, si L es 19F, dicho compuesto contiene exactamente un átomo de 19F unido a un átomo de carbono hibridizado con sp3, en donde n es un entero de 0 a 6, preferentemente 1-3, más preferentemente 1-2, y en donde m es un entero de 0 a 4, preferentemente entre 0 y 2, más preferentemente 0-1, y en donde e y f son enteros de 0 a 1, con la condicion de que al menos uno de e y f es 1, incluyendo todas las formas isoméricas de dicho compuesto, incluyendo pero sin limitarse a enantiomeros y diastereoisomeros así como también mezclas racémicas, y cualquier sal, éster, amida, complejo o prodroga aceptable para uso farmacéutico del mismo. Reivindicacion 15: Un método para la síntesis de un compuesto como se define en la reivindicacion 13 o la reivindicacion 14, caracterizado porque comprende hacer reaccionar un compuesto de acuerdo con la reivindicacion 9 o 12 con un agente de F-fluoracion, donde F = 18F o 19F. Reivindicacion 22: Una composicion, caracterizada porque comprende un compuesto de acuerdo con cualquiera de las reivindicaciones 1-14 y un vehículo o diluyente aceptable para uso farmacéutico. Reivindicacion 27: Uso de un compuesto de acuerdo con cualquiera de las reivindicaciones 1-14, preferiblemente un compuesto de acuerdo con la reivindicacion 13 o 14, o una composicion de acuerdo con cualquiera de las reivindicaciones 22, 23, 24 o25, caracterizado porque es para la fabricacion de un medicamento para el tratamiento y/o el diagnostico y/o la formacion de imágenes de enfermedades del sistema nervioso central (CNS). Reivindicacion 30: Un método para detectar la presencia de monoamina oxidasa en el cuerpo de un paciente, preferiblemente para el diagnostico por imágenes de una enfermedad del sistema nervioso central en un paciente, caracterizado porque comprende introducir en el cuerpo de un paciente una cantidad detectable de un compuesto de acuerdo con la reivindicacion 13 o una composicion de acuerdo con la reivindicacion 23, y detectar dicho compuesto o dicha composicion por tomografía por emision de positrones (PET).
ARP080104633A 2007-10-26 2008-10-24 Compuestos para usar en la formacion de imagenes el diagnostico y/o el tratamiento de enfermedades del sistema nervioso central o de tumores, metodos de preparacion, composiciones farmaceuticas, usos y metodos de deteccion de monoamina oxidasa. AR071054A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07021042A EP2053033A1 (en) 2007-10-26 2007-10-26 Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors

Publications (1)

Publication Number Publication Date
AR071054A1 true AR071054A1 (es) 2010-05-26

Family

ID=39027113

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104633A AR071054A1 (es) 2007-10-26 2008-10-24 Compuestos para usar en la formacion de imagenes el diagnostico y/o el tratamiento de enfermedades del sistema nervioso central o de tumores, metodos de preparacion, composiciones farmaceuticas, usos y metodos de deteccion de monoamina oxidasa.

Country Status (16)

Country Link
US (4) US20100233086A1 (es)
EP (4) EP2053033A1 (es)
JP (1) JP5710972B2 (es)
KR (1) KR101611389B1 (es)
CN (2) CN105175293A (es)
AR (1) AR071054A1 (es)
AU (1) AU2008315950C1 (es)
BR (1) BRPI0818841A2 (es)
CA (1) CA2703080C (es)
ES (1) ES2643487T3 (es)
HK (1) HK1145316A1 (es)
IL (1) IL204584A0 (es)
MX (1) MX2010004568A (es)
RU (1) RU2505528C2 (es)
TW (1) TWI543769B (es)
WO (1) WO2009052970A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2053033A1 (en) * 2007-10-26 2009-04-29 Bayer Schering Pharma AG Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
KR101619564B1 (ko) * 2009-04-23 2016-05-10 바이엘 파마 악티엔게젤샤프트 Ｆ-18 표지 ｐｅｔ 추적자에 관한 신규 전구체 분자
EP2450332A1 (en) 2010-10-22 2012-05-09 Bayer Pharma Aktiengesellschaft Compounds for use in Imaging, diagnosing and/or treatment of diseases of the central nervous system (F-D2-Deprenyl)
RU2013147022A (ru) * 2011-03-23 2015-04-27 Пирамаль Имэджинг Са Соединения для применения визуализации, диагностики и/или лечения заболеваний центральной нервной системы
EP2744771B1 (en) 2011-08-19 2020-10-21 The Trustees of Princeton University C-halogen bond formation
US20150031768A1 (en) * 2011-08-19 2015-01-29 The Trustees Of Princeton University C-halogen bond formation
US9187484B2 (en) 2012-05-02 2015-11-17 Southern Research Institute Triazolopyridazine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof
WO2015054476A1 (en) * 2013-10-09 2015-04-16 The Trustees Of Princeton University C-halogen bond formation
WO2016097351A1 (en) * 2014-12-19 2016-06-23 Ge Healthcare Limited 18f labelled thiazolylhydrazone derivatives
US11391853B2 (en) * 2018-06-20 2022-07-19 BWXT Isotope Technology Group, Inc. System and method for evaluating elution efficiency and radiopurity of tc-99m generators
GB202108605D0 (en) * 2021-06-16 2021-07-28 Ge Healthcare Uk Ltd Effect of water content

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3160664A (en) * 1959-04-10 1964-12-08 Miles Lab Acetylenic omega-haloalkylamines
US3253037A (en) * 1962-06-19 1966-05-24 Ciba Geigy Corp N-2-alkynyl-amino-benzocylo-alkanes
GB1121857A (en) * 1965-01-05 1968-07-31 Science Union & Cie New phenylisopropylamine derivatives and process for their preparation and pharmaceutical preparations of such derivatives
US4377587A (en) * 1980-07-25 1983-03-22 Ciba-Geigy Corporation Arylamine derivatives and use thereof as microbicides
US4448773A (en) * 1981-04-29 1984-05-15 Ciba-Geigy Corporation Microbicidal N-alkoxycarbonyl-alkyl-N-substituted acetyl-anilines and -naphthylamines
HU207282B (en) * 1984-05-31 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing phenyl-alkyl-amine derivatives and pharmaceutical compositions containing them
IT1240676B (it) * 1990-04-24 1993-12-17 Agrimont Spa Composizioni ad attivita' erbicida
US5169868A (en) * 1991-03-01 1992-12-08 University Of Saskatchewan Aliphatic propargylamines as specific mao-b inhibitors
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
IL99759A (en) * 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
HUT63579A (en) * 1991-12-20 1993-09-28 Chinoin Gyogyszer Es Vegyeszet Process for producing double-phase pharmaceutical compositions suitable for treating diseases occurring during neurodegenerative processes
JPH0797450A (ja) * 1993-09-29 1995-04-11 Mitsubishi Cable Ind Ltd クラウン系ポリマーの製造方法および固体電解質
TR199700878T1 (xx) 1995-03-02 1998-01-21 R.P. Scherer Limited Monamin oksidaz B inhibit�rleri i�eren farmakotik kompozisyonlar.
AU2010299A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
AU2012199A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
AU2092599A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
US8097608B2 (en) * 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
EP1890690A4 (en) * 2005-06-02 2010-06-02 Jenrin Discovery MAO-B INHIBITORS FOR TREATING OBESITY
US7956220B2 (en) * 2005-07-01 2011-06-07 Jenrin Discovery MAO-B inhibitors useful for treating obesity
US7833259B2 (en) 2005-07-25 2010-11-16 Cook Incorporated Fenestrated endoluminal stent system
CA2654369C (en) * 2006-06-21 2014-10-14 Ge Healthcare Limited Radiopharmaceutical products
FR2918370B1 (fr) * 2007-07-02 2009-08-28 Servier Lab Nouveaux derives naphtaleniques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CL2008002242A1 (es) * 2007-07-31 2009-08-21 Bayer Cropscience Ag Compuestos derivados de n-cicloalquil-n-carboxamida, tiocarboxamida, biciclicas o derivados de carboximidamida n-sustituida; composicion fungicida; y metodo para controlar los hongos fitopatogenos de los cultivos.
EP2053033A1 (en) * 2007-10-26 2009-04-29 Bayer Schering Pharma AG Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
EP2450332A1 (en) * 2010-10-22 2012-05-09 Bayer Pharma Aktiengesellschaft Compounds for use in Imaging, diagnosing and/or treatment of diseases of the central nervous system (F-D2-Deprenyl)

Also Published As

Publication number Publication date
RU2505528C2 (ru) 2014-01-27
EP2374779A1 (en) 2011-10-12
WO2009052970A3 (en) 2009-07-02
CN101835728B (zh) 2016-03-09
IL204584A0 (en) 2010-11-30
KR20100075547A (ko) 2010-07-02
AU2008315950B2 (en) 2013-11-14
US10266506B2 (en) 2019-04-23
EP2217549B1 (en) 2017-04-19
US20150030539A1 (en) 2015-01-29
AU2008315950A1 (en) 2009-04-30
EP2388245B1 (en) 2017-07-12
WO2009052970A2 (en) 2009-04-30
US20100233086A1 (en) 2010-09-16
BRPI0818841A2 (pt) 2015-04-22
CA2703080C (en) 2017-02-14
TW200932276A (en) 2009-08-01
US8784775B2 (en) 2014-07-22
MX2010004568A (es) 2012-09-28
EP2217549A2 (en) 2010-08-18
JP5710972B2 (ja) 2015-04-30
AU2008315950C1 (en) 2014-05-15
US20180022719A1 (en) 2018-01-25
CN101835728A (zh) 2010-09-15
CN105175293A (zh) 2015-12-23
KR101611389B1 (ko) 2016-04-19
US9682944B2 (en) 2017-06-20
TWI543769B (zh) 2016-08-01
JP2011501756A (ja) 2011-01-13
HK1145316A1 (zh) 2011-04-15
EP2053033A1 (en) 2009-04-29
US20090191129A1 (en) 2009-07-30
ES2643487T3 (es) 2017-11-23
CA2703080A1 (en) 2009-04-30
RU2010120799A (ru) 2011-12-10
EP2388245A1 (en) 2011-11-23

Similar Documents

Publication Publication Date Title
AR071054A1 (es) Compuestos para usar en la formacion de imagenes el diagnostico y/o el tratamiento de enfermedades del sistema nervioso central o de tumores, metodos de preparacion, composiciones farmaceuticas, usos y metodos de deteccion de monoamina oxidasa.
AR073263A1 (es) Derivados de piridina y su uso en diagnostico de imagenes mediante pet
ES2759312T3 (es) Compuestos de aminocarbonilcarbamato
AR047972A1 (es) Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas.
UY30112A1 (es) Nuevos benzotiazoles sustitidos por heteroarilo
TW200738698A (en) Organic compounds
KR101636245B1 (ko) 신규한 [ｆ-１８]-표지된 ｌ-글루탐산- 및 ｌ-글루타민 유도체 (ｉ), 그의 용도 및 그의 제조 방법
MX2015015893A (es) 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen.
PE20091723A1 (es) Derivados de acido l-glutamico marcado con [18 f] y l-glutamina marcada con [18f]
EA200970510A1 (ru) Гетеромоноциклическое соединение и его применение
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
RU2007108762A (ru) Диагностические соединения
CN103002924A (zh) 用于合成和使用造影剂的组合物、方法和系统
TW200700061A (en) Organic compounds
ES2929140T3 (es) Imidazoles sustituidos con fenilo y piridinilo como moduladores de RORgammat
JP2009149678A (ja) 腫瘍画像化化合物
HUE030172T2 (en) Tau imaging probe
MX2019014368A (es) Agentes de imagenologia nuevos para tomografia de emision de positrones (pet) sustituidos con deuterio y su aplicacion farmacologica.
EA200901142A1 (ru) 18f фторбензоильные меченые биологически активные соединения в качестве диагностических визуализирующих средств, а также бензотриазол-1-илоксибензоильные, 2,5-(диоксопирролидин-1-илокси)бензоильные и триметиламмониобензоильные предшественники
MY147347A (en) Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
AR074593A1 (es) Benzotiazol amidas para la deteccion del peptido beta amiloide
BRPI0416564A (pt) novas prostamidas para o tratamento de glaucoma e doenças relacionadas
CA2599321A1 (en) Radioactive halogen-labeled phenyloxyaniline derivatives
AR043427A1 (es) Derivados de acido alcanoico sustituidos con aril-cicloalquilo, procedimientos para su obtencion, y su empleo como medicamentos
ES2852724T3 (es) Derivados de dihidronaftaleno útiles en el tratamiento de enfermedades mediadas por S1P5

Legal Events

Date Code Title Description
FA Abandonment or withdrawal